SCHEMBL6533164

SCHEMBL6533164

COC(=O)CCc1nc(-c2ccc(CN(C)C)n2C)no1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.41
ATM Q13315 1/20 0.41
HPGD P15428 5/20 0.39
ALDH1A1 P00352 5/20 0.39
TSHR P16473 2/20 0.39
NPC1 O15118 2/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2C19 P33261 2/20 0.39
RAB9A P51151 1/20 0.39
POLB P06746 2/20 0.39
GAA P10253 1/20 0.38
ALOX15 P16050 1/20 0.38
HSD17B10 Q99714 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAPT P10636 3/20 0.38
TP53 P04637 2/20 0.37
MITF O75030 1/20 0.37
NCOA3 Q9Y6Q9 1/20 0.37
CYP2C9 P11712 1/20 0.37
MCL1 Q07820 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6326515 0.88 TSHR (0.48) LMNAATMHPGDALDH1A1TSHR
SCHEMBL6324441 0.76 HPGD (0.45) LMNAATMHPGDALDH1A1NPC1
SCHEMBL6323359 0.72 HPGD (0.43) LMNAATMHPGDALDH1A1POLB
SCHEMBL4564362 0.71 HPGD (0.68) LMNAATMHPGDALDH1A1TSHR
SCHEMBL6333033 0.70 LMNA (0.61) LMNAATMHPGDALDH1A1TSHR
SCHEMBL6328188 0.69 HPGD (0.41) LMNAATMHPGDALDH1A1TSHR
SCHEMBL6324732 0.69 TSHR (0.53) LMNAATMHPGDALDH1A1TSHR
SCHEMBL6325140 0.69 LMNA (0.58) LMNAATMHPGDALDH1A1TSHR
SCHEMBL6328296 0.68 HPGD (0.46) LMNAATMHPGDALDH1A1NPC1
SCHEMBL6326028 0.68 LMNA (0.57) LMNAATMHPGDALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1423120-A4 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORP (US) 2005-12-28 EP disclosed
EP-1423120-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2004-06-02 EP disclosed
US-20040087588-A1 Parp inhibitors ICOS CORPORATION 2004-05-06 US disclosed
WO-2003015785-A1 2H-PHTHALAZIN-1-ONES AND METHODS FOR USE THEREOF ICOS CORPORATION (US) 2003-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087588-A1 Parp inhibitors PARP1, PARP2, PARP11 LMNA 448/4885ATM 414/4885HPGD 539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.